Zolgensma Global Managed Access Program

[anonymous]

So apparently there is no longer a Zolgensma Managed Access Program globally? What are patients supposed to do in countries with no access? Did anyone else miss this? Zolgensma® Global Managed Access Program (gMAP).

 

[anonymous]

So apparently there is no longer a Zolgensma Managed Access Program globally? What are patients supposed to do in countries with no access? Did anyone else miss this? Zolgensma® Global Managed Access Program (gMAP).

"We are continuing working to develop concepts for sustainable partnerships in countries that lack access and that have an interest and willingness to invest in co-creating solutions to broaden access to Zolgensma."

Translation: sales of Zolgensma are declining and they no longer want to give it away for free.

Price Vas paid for Avexis in 2019 = $8.7b
Cumulative Zolgensma sales since 2019 = aprox. $6b

All that hype and bullshit on Zolgensma and they will struggle to break even.

 

[anonymous]

"We are continuing working to develop concepts for sustainable partnerships in countries that lack access and that have an interest and willingness to invest in co-creating solutions to broaden access to Zolgensma."

Translation: sales of Zolgensma are declining and they no longer want to give it away for free.

Price Vas paid for Avexis in 2019 = $8.7b
Cumulative Zolgensma sales since 2019 = aprox. $6b

All that hype and bullshit on Zolgensma and they will struggle to break even.

Interesting! What about the upcoming intrathecal version? Also, how is Vas still in charge? Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA

 

[anonymous]

Interesting! What about the upcoming intrathecal version? Also, how is Vas still in charge? Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA

there is now a lot of competition in this space and do SMA Type 2 patients need a $2M+ gene therapy?

 

[anonymous]

there is now a lot of competition in this space and do SMA Type 2 patients need a $2M+ gene therapy?

Many SMA patients in wealthy countries are now even on dual therapies so there's still space for Zolgensma. Especially with the intrathecal coming. But it will be interesting to see how the IT version is priced. After delay with FDA, Novartis touts pivotal trial win for intrathecal Zolgensma in older SMA patients